Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL
Studies in humans and mice have shown that increased expression of apolipoprotein C-I (apoC-I) results in combined hyperlipidemia with a more pronounced effect on triglycerides (TGs) compared with total cholesterol (TC). The aim of this study was to elucidate the main reason for this effect using hu...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2005-02-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520340633 |
id |
doaj-ddbee51758b940aab6d627fadf1e2612 |
---|---|
record_format |
Article |
spelling |
doaj-ddbee51758b940aab6d627fadf1e26122021-04-27T04:46:34ZengElsevierJournal of Lipid Research0022-22752005-02-01462297306Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPLJimmy F.P. Berbée0Caroline C. van der Hoogt1Deepa Sundararaman2Louis M. Havekes3Patrick C.N. Rensen4Netherlands Organization for Applied Scientific Research-Prevention and Health, Gaubius Laboratory, 2301 CE Leiden, The Netherlands; Department of General Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsNetherlands Organization for Applied Scientific Research-Prevention and Health, Gaubius Laboratory, 2301 CE Leiden, The Netherlands; Department of General Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsNetherlands Organization for Applied Scientific Research-Prevention and Health, Gaubius Laboratory, 2301 CE Leiden, The Netherlands; Department of General Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsNetherlands Organization for Applied Scientific Research-Prevention and Health, Gaubius Laboratory, 2301 CE Leiden, The Netherlands; Department of General Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsNetherlands Organization for Applied Scientific Research-Prevention and Health, Gaubius Laboratory, 2301 CE Leiden, The Netherlands; Department of General Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsStudies in humans and mice have shown that increased expression of apolipoprotein C-I (apoC-I) results in combined hyperlipidemia with a more pronounced effect on triglycerides (TGs) compared with total cholesterol (TC). The aim of this study was to elucidate the main reason for this effect using human apoC-I-expressing (APOC1) mice. Moderate plasma human apoC-I levels (i.e., 4-fold higher than human levels) caused a 12-fold increase in TG, along with a 2-fold increase in TC, mainly confined to VLDL. Cross-breeding of APOC1 mice on an apoE-deficient background resulted in a marked 55-fold increase in TG, confirming that the apoC-I-induced hyperlipidemia cannot merely be attributed to blockade of apoE-recognizing hepatic lipoprotein receptors. The plasma half-life of [3H]TG-VLDL-mimicking particles was 2-fold increased in APOC1 mice, suggesting that apoC-I reduces the lipolytic conversion of VLDL. Although total postheparin plasma LPL activity was not lower in APOC1 mice compared with controls, apoC-I was able to dose-dependently inhibit the LPL-mediated lipolysis of [3H]TG-VLDL-mimicking particles in vitro with a 60% efficiency compared with the main endogenous LPL inhibitor apoC-III. Finally, purified apoC-I impaired the clearance of [3H]TG-VLDL-mimicking particles independent of apoE-mediated hepatic uptake in lactoferrin-treated mice.Therefore, we conclude that apoC-I is a potent inhibitor of LPL-mediated TG-lipolysis.http://www.sciencedirect.com/science/article/pii/S0022227520340633fatty acidslipid metabolismtriglyceridesapolipoprotein C-Ivery low density lipoproteinlipoprotein lipase |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jimmy F.P. Berbée Caroline C. van der Hoogt Deepa Sundararaman Louis M. Havekes Patrick C.N. Rensen |
spellingShingle |
Jimmy F.P. Berbée Caroline C. van der Hoogt Deepa Sundararaman Louis M. Havekes Patrick C.N. Rensen Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL Journal of Lipid Research fatty acids lipid metabolism triglycerides apolipoprotein C-I very low density lipoprotein lipoprotein lipase |
author_facet |
Jimmy F.P. Berbée Caroline C. van der Hoogt Deepa Sundararaman Louis M. Havekes Patrick C.N. Rensen |
author_sort |
Jimmy F.P. Berbée |
title |
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL |
title_short |
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL |
title_full |
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL |
title_fullStr |
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL |
title_full_unstemmed |
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL |
title_sort |
severe hypertriglyceridemia in human apoc1 transgenic mice is caused by apoc-i-induced inhibition of lpl |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2005-02-01 |
description |
Studies in humans and mice have shown that increased expression of apolipoprotein C-I (apoC-I) results in combined hyperlipidemia with a more pronounced effect on triglycerides (TGs) compared with total cholesterol (TC). The aim of this study was to elucidate the main reason for this effect using human apoC-I-expressing (APOC1) mice. Moderate plasma human apoC-I levels (i.e., 4-fold higher than human levels) caused a 12-fold increase in TG, along with a 2-fold increase in TC, mainly confined to VLDL. Cross-breeding of APOC1 mice on an apoE-deficient background resulted in a marked 55-fold increase in TG, confirming that the apoC-I-induced hyperlipidemia cannot merely be attributed to blockade of apoE-recognizing hepatic lipoprotein receptors. The plasma half-life of [3H]TG-VLDL-mimicking particles was 2-fold increased in APOC1 mice, suggesting that apoC-I reduces the lipolytic conversion of VLDL. Although total postheparin plasma LPL activity was not lower in APOC1 mice compared with controls, apoC-I was able to dose-dependently inhibit the LPL-mediated lipolysis of [3H]TG-VLDL-mimicking particles in vitro with a 60% efficiency compared with the main endogenous LPL inhibitor apoC-III. Finally, purified apoC-I impaired the clearance of [3H]TG-VLDL-mimicking particles independent of apoE-mediated hepatic uptake in lactoferrin-treated mice.Therefore, we conclude that apoC-I is a potent inhibitor of LPL-mediated TG-lipolysis. |
topic |
fatty acids lipid metabolism triglycerides apolipoprotein C-I very low density lipoprotein lipoprotein lipase |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520340633 |
work_keys_str_mv |
AT jimmyfpberbee severehypertriglyceridemiainhumanapoc1transgenicmiceiscausedbyapociinducedinhibitionoflpl AT carolinecvanderhoogt severehypertriglyceridemiainhumanapoc1transgenicmiceiscausedbyapociinducedinhibitionoflpl AT deepasundararaman severehypertriglyceridemiainhumanapoc1transgenicmiceiscausedbyapociinducedinhibitionoflpl AT louismhavekes severehypertriglyceridemiainhumanapoc1transgenicmiceiscausedbyapociinducedinhibitionoflpl AT patrickcnrensen severehypertriglyceridemiainhumanapoc1transgenicmiceiscausedbyapociinducedinhibitionoflpl |
_version_ |
1721506395019280384 |